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B-type Natriuretic Peptides for the Prediction of Cardiovascular
Events in Patients With Stable Coronary Heart Disease: The Heart
and Soul Study
Rakesh K. Mishra, MD; Alexis L. Beatty, MD, MAS; Rajesh Jaganath, MD; Mathilda Regan, MPH; Alan H.B. Wu, PhD; Mary A. Whooley, MD
Background-—Brain-type natriuretic peptide (BNP) and the amino-terminal fragment of its prohormone (NT-proBNP) are known
predictors of cardiovascular outcomes in patients with coronary heart disease; however, the relative prognostic value of these 2
biomarkers for secondary events remains unclear.
Methods and Results-—In 983 participants with stable coronary heart disease, we evaluated the association of BNP and NT-
proBNP with time to hospitalization for heart failure, nonfatal myocardial infarction, stroke or transient ischemic attack,
cardiovascular death, and combined major adverse cardiovascular events (MACE). During an average follow-up of 6.53.3 years,
both BNP and NT-proBNP were associated with increased risk of MACE in a multivariable-adjusted model (hazard ratio per standard
deviation of log BNP: 1.58; 95% CI: 1.32 to 1.89; hazard ratio per standard deviation of log NT-proBNP: 1.84; 95% CI: 1.52 to 2.24).
When added to traditional risk factors, NT-proBNP predicted MACE better than BNP (C statistic: 0.76 versus 0.72, P<0.001).
Similarly, the addition of NT-proBNP resulted in a greater net reclassification improvement for predicting MACE than the addition of
BNP (65% for NT-proBNP, 56% for BNP).
Conclusions-—Both BNP and NT-proBNP were significant predictors of MACE in stable coronary heart disease; however, NT-
proBNP was superior to BNP for net risk reclassification for MACE. ( J Am Heart Assoc. 2014;3:e000907 doi: 10.1161/
JAHA.114.000907)
Key Words: adverse cardiovascular outcomes • BNP • NT-proBNP • risk assessment • stable coronary heart disease
B rain natriuretic peptide (BNP) and the amino-terminalfragment of its prohormone (NT-proBNP) are released in
equimolar amounts from the myocardium.1 Both peptides
predict adverse cardiovascular (CV) events in heart failure
(HF),2 acute coronary syndromes,3,4 and stable coronary heart
disease (CHD)5–10; however, the relative prognostic utility of
one versus the other for secondary events in patients with
stable CHD is unclear.
Prior studies comparing the prognostic value of BNP and
NT-proBNP in stable CHD have yielded conflicting results. One
study of patients with stable CHD found that both biomarkers
performed equally well for the prediction of HF and all-cause
mortality during 1 year of follow-up.9 In another study, both
BNP and NT-proBNP were independently related to incident
HF, but only NT-proBNP was associated with an increased risk
of stroke and CV mortality.8 These findings suggest that
although BNP and NT-proBNP are related, they may not be
interchangeable as predictors of adverse CV events. In
addition to differences in biologic half-lives, assay stability,
and clearance mechanisms, there may be differences in
secretion patterns in response to myocardial hypoxia or in the
setting of structural heart disease.11–13 Because of the
conflicting data on differences in the prognostic value of BNP
and NT-proBNP, we sought to evaluate the independent
prognostic value of BNP and NT-proBNP in well-characterized,
stable outpatients with CHD enrolled in a prospective cohort
study with long-term follow-up.
Methods
Study Participants
The Heart and Soul Study is a prospective cohort study
evaluating the role of psychosocial factors on CV outcomes
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in 1024 patients with CHD. Methods for this study have
been previously described in detail.14 Participants with CHD
were included and defined as (1) history of myocardial
infarction, (2) angiographic evidence of at least 50%
stenosis in 1 coronary vessel or more, (3) evidence of
inducible ischemia by treadmill electrocardiography or
nuclear perfusion stress imaging, or (4) a history of
coronary revascularization. Patients were excluded if they
were unable to walk more than 1 block, had a history of
acute coronary syndrome within the prior 6 months, or
intended to move from the locality in the subsequent
3 years. We further limited analysis to the 983 participants
with both BNP and NT-proBNP levels measured at baseline.
The institutional review board at each of the sites approved
this protocol. All participants provided written informed
consent.
Measurement of NT-proBNP and BNP Levels
Blood samples were drawn after an overnight fast, with
patients instructed to continue their regularly prescribed
medications. Samples were originally collected during 2000 to
2002 and stored at 70°C until January 2005. The Roche
Diagnostics Elecsys proBNP assay was used to measure NT-
proBNP. The assay ranges from 5 to 35 000 pg/mL. The
intra-assay and interassay coefficients of variation ranged,
respectively, from 2.7% and 3.2% at NT-proBNP concentra-
tions of 175 pg/mL to 1.8% and 2.3% at NT-proBNP
concentrations of 4962 pg/mL.
We used the Alere Triage BNP fluorescence immunoas-
say (Alere Inc) to measure BNP in frozen plasma sam-
ples thawed to room temperature in November 2013. Of
note, the plasma samples used to measure BNP had
undergone 1 freeze–thaw cycle previously. The assay range
was 5 to 5000 pg/mL. The interassay coefficient of
variation was 10.1% for 28.8 pg/mL, 12.4% for 586 pg/
mL, and 16.2% for 1180 pg/mL. The laboratory technicians
who measured BNP and NT-proBNP at 2 different times
were located at 2 different sites and were blinded to the
characteristics of the patients and the results of the
echocardiographic and the other natriuretic peptide mea-
surements.
Other Measurements
Self-reported age, sex, ethnicity, past medical history, and
smoking status were assessed by questionnaire. Glomerular
filtration rate was calculated using the Chronic Kidney
Disease Epidemiolology Collaboration equation.15 Levels of
high-density lipoprotein cholesterol and low-density lipopro-
tein cholesterol were determined from plasma samples drawn
after an overnight fast.
Echocardiography
A complete resting 2-dimensional echocardiogram and Dopp-
ler ultrasound examination was performed using an Acuson
Sequoia Ultrasound System (Siemens Medical Solutions USA,
Inc). Standard 2-dimensional parasternal short axis, apical 2-
chamber, apical 4-chamber, and subcostal views were
obtained. All echocardiograms were interpreted by a single
expert reader.
Left ventricular (LV) end-diastolic and end-systolic volumes
were approximated using the modified biplane methods of
discs. LV ejection fraction was calculated as follows:
ðLV end-diastolic volume LV end-systolic volumeÞ
LV end-diastolic volume
:
The truncated ellipsoid method was used to estimate LV
mass, which was then indexed to body surface area.16 Mitral
inflow velocities (E and A) were calculated using pulse-wave
Doppler in the apical 4-chamber view, with the sample volume
positioned between themitral leaflet tips. Mitral inflow E- and A-
wave velocities, E-wave deceleration time, and the ratio of
pulmonary venous systolic-to-diastolic flow velocity-time inte-
gral were used to group LV diastolic function into categories of
“normal,” “mild dysfunction,” “moderate dysfunction,” or
“severe dysfunction.”17 Of the 983 participants, 149 partici-
pants could not be assigned unambiguously to an LV diastolic
function category and thushadamissing value for this covariate.
Clinical Outcomes
The outcome in this study was time to HF hospitalization,
nonfatal myocardial infarction (MI), stroke (cerebral vascu-
lar accident [CVA]) or transient ischemic attack (TIA), and CV
death. HF was defined as hospitalization for signs and
symptoms of HF. MI was defined using standard
diagnostic criteria.18 CVA/TIA was defined as a new
neurological deficit not known to be secondary to brain
trauma, tumor, infection, or other cause. Death and cause of
death were verified by death certificates and review of
medical records. The outcome assessment and adjudication
process has been described previously in greater detail.5
Statistical Analyses
We modeled BNP and NT-proBNP as quartiles and as log-
transformed linear variables. Samples with values for either
BNP or NT-proBNP below the lower limit of detection (5 pg/
mL) were entered into the analyses as 5 pg/mL. Differences
in participant characteristics were compared using chi-square
tests for dichotomous variables and analysis of variance for
continuous variables.
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We used demographically adjusted and multivariable-
adjusted Cox proportional hazards models to evaluate the
association of BNP and NT-proBNP with the outcome
variables. The multivariable models were adjusted for Fra-
mingham secondary events clinical risk factors: for men,
these include age, natural log of the ratio of total cholesterol
to high-density lipoprotein cholesterol, and diabetes; for
women, these include age, natural log of the ratio of total
cholesterol to high-density lipoprotein cholesterol, natural log
of systolic blood pressure, diabetes, and smoking.19 The
multivariable models were also adjusted for traditional CV risk
factors including age, sex, ethnicity, current smoking status,
history of diabetes mellitus, history of HF, history of MI, body
mass index, systolic blood pressure, low-density lipoprotein,
estimated glomerular filtration rate, LV mass index, LV
ejection fraction, and LV diastolic function category. For the
quartile analysis, the entire sample (quartiles I through IV) was
included, and the P value for the trend of hazard ratios across
quartiles, with quartile I as the referent, was calculated.
We evaluated the C statistic, which is equivalent to the
area under the receiver operating characteristic curve, for
BNP and NT-proBNP as linear log-transformed variables in
Framingham secondary events clinical risk factor–adjusted
logistic regression models for the prediction of adverse CV
outcomes. We further determined the incremental prognostic
value of BNP and NT-proBNP using the category-free net
reclassification improvement (NRI) analysis. A baseline mul-
tivariable logistic regression model with Framingham second-
ary events clinical risk factors was used to generate the
probability of each participant having an adverse CV outcome
(P0). The probabilities were then recalculated for the outcome
with the addition of BNP or NT-proBNP into the clinical model
(P1). If P1>P0, then the person was considered to have an
upward reclassification, and if P1<P0 then the person was
considered to have a downward reclassification. If P1=P0, then
no reclassification occurred. The NRI was then calculated using
the following formula: NRI=[P (up|outcome)P (down|out-
come)]+[P (down|nonoutcome)P (up|nonoutcome)].20–22
Finally, we quantified the separation of events from none-
vents by the addition of BNP or NT-proBNP into the clinical
model by calculating the integrated discrimination improve-
ment (IDI). Mean probabilities were calculated for an event in
those participants who develop events and for an event in
those who do not develop events using the baseline
multivariable logistic regression model with Framingham
secondary events clinical risk factors (old model) and the
clinical model plus BNP or NT-proBNP (new model). The IDI was
then calculated for BNP and for NT-proBNP using the formula
IDI=(Pnew, eventsPnew, nonevents)(Pold, eventsPold, nonevents),
in which Pnew, events is the mean of the new model-based
predicted probabilities of an event for those who develop
events, Pold, events is the corresponding quantity based on the
old model without BNP or NT-proBNP, Pnew, nonevents is the
mean of the new model-based predicted probabilities of an
event for those who do not develop events, and Pold, nonevents
is the corresponding quantity based on the old model without
BNP or NT-proBNP. Calibration metrics for the risk models
were estimated using the Hosmer-Lemeshow goodness-of-fit
test and deciles of fitted risk values. All analyses were
performed using IBM SPSS version 20.0 and STATA version
12.0 (StataCorp).
Table 1. Baseline Characteristics of the 983 Study
Participants With Stable Coronary Heart Disease*
Age, y 67 (11)
Male (n, %) 800 (81)
Ethnicity (n, %)
White 592 (60)
Black 160 (16)
Hispanic 113 (12)
Other 117 (12)
Diabetes mellitus (n, %) 257 (26)
Hypertension (n, %) 691 (70)
Current smoking (n, %) 195 (20)
History of heart failure (n, %) 173 (18)
History of myocardial infarction (n, %) 524 (53)
BMI, kg/m2 28 (5)
SBP, mm Hg 133 (21)
DBP, mm Hg 75 (11)
LDL, mg/dL 104 (34)
HDL, mg/dL 46 (14)
Creatinine, mg/dL 1.14 (0.64)
eGFR, mL/min 71 (22)
NT-proBNP†, pg/mL 174 (74, 460)
BNP†, pg/mL 42 (18, 102)
LV mass index, g/m2 100 (34)
LVEF, % 62 (10)
LV diastolic function‡ (n, %)
Normal 508 (61)
Impaired relaxation 215 (22)
Pseudo-normal 59 (6)
Restrictive 52 (5)
BNP indicates brain-type natriuretic peptide; BMI, body mass index; DBP, diastolic blood
pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL,
low-density lipoprotein; LV, left ventricular; LVEF, left ventricular ejection fraction; NT-
proBNP, amino-terminal fragment of the BNP prohormone; SBP, systolic blood pressure.
*Mean (SD) reported for continuous variables.
†Reported as median (interquartile range)
‡Of the 983 participants, 149 did not have adequate echocardiographic information for
categorization of diastolic function.
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Results
The study participants were predominantly older, white, and
male with a high prevalence of hypertension and previous MI
(Table 1). Most participants did not report a history of HF.
Levels of BNP and NT-proBNP were strongly correlated with
each other (r=0.90; P<0.001).
During a mean follow-up of 6.53.3 years, there were 133
MIs, 178 HF hospitalizations, 67 CVA/TIAs, 144 CV deaths,
and 346 MACE.
When modeled as continuous variables, both BNP and NT-
proBNP were strongly associated with HF hospitalization,
nonfatal MI, CVA/TIA, CV death, and MACE (Table 2). These
associations were attenuated but remained significant with
adjustment for clinical risk factors. In the fully adjusted
models that included estimated glomerular filtration rate and
LV structural and functional parameters, both BNP and
NT-proBNP were significantly associated with HF hospitaliza-
tion, nonfatal MI, CV death, and MACE, but neither was
associated with CVA/TIA.
Participants with levels of BNP or NT-proBNP in the highest
quartile had the greatest incidence of these events during the
follow-up period (Figure). In a demographically adjusted
model, the highest quartiles of BNP and NT-proBNP were
both strongly associated with an increased risk of HF
hospitalization, MI, CVA/TIA, and CV death and the combined
outcome when compared with their respective lowest quar-
tiles (Table 3). With further adjustment for additional clinical
risk factors, the associations of the highest quartiles of BNP
and NT-proBNP with HF hospitalization (15-fold and 26-fold
increased risk, respectively), nonfatal MI (approximately 4-fold
increased risk for both), CVA/TIA (approximately 2.5-fold and
4-fold increased risk, respectively), CV death (4-fold and 7-fold
increased risk, respectively), and MACE (3-fold and 4-fold
Table 2. Association of BNP and NT-proBNP (Entered as Log-Transformed Continuous Variables, Per 1SD Increase) With
Cardiovascular Outcomes
Log BNP Log NT-proBNP
HR* (95% CI) P Value HR* (95% CI) P Value
HF
Model 1* 3.18 (2.65 to 3.80) <0.001 3.14 (2.70 to 3.65) <0.001
Model 2† 3.08 (2.56 to 3.70) <0.001 3.14 (2.69 to 3.68) <0.001
Model 3‡ 2.81 (2.12 to 3.74) <0.001 2.81 (2.09 to 3.78) <0.001
Nonfatal MI
Model 1* 1.65 (1.36 to 2.00) <0.001 1.80 (1.51 to 2.16) <0.001
Model 2† 1.60 (1.32 to 1.95) <0.001 1.76 (1.46 to 2.12) <0.001
Model 3‡ 1.43 (1.09 to 1.88) 0.01 1.77 (1.30 to 2.41) <0.001
CVA/TIA
Model 1* 1.64 (1.25 to 2.15) 0.001 1.66 (1.28 to 2.14) <0.001
Model 2† 1.64 (1.24 to 2.16) <0.001 1.68 (1.29 to 2.18) <0.001
Model 3‡ 1.37 (0.93 to 2.01) 0.11 1.40 (0.92 to 2.13) 0.12
CV death
Model 1* 1.90 (1.57 to 2.30) <0.001 2.36 (1.99 to 2.81) <0.001
Model 2† 1.90 (1.56 to 2.32) <0.001 2.40 (2.00 to 2.89) <0.001
Model 3‡ 1.61 (1.22 to 2.13) 0.001 2.19 (1.63 to 2.94) <0.001
Any event
Model 1* 1.96 (1.73 to 2.21) <0.001 2.20 (1.97 to 2.46) <0.001
Model 2† 1.94 (1.71 to 2.20) <0.001 2.19 (1.95 to 2.45) <0.001
Model 3‡ 1.58 (1.32 to 1.89) <0.001 1.84 (1.52 to 2.24) <0.001
BNP indicates brain-type natriuretic peptide; CI, confidence interval; CV, cardiovascular; CVA, cerebral vascular accident; HF, heart failure; HR, hazard ratio; MI, myocardial infarction;
NT-proBNP, amino-terminal fragment of the BNP prohormone; TIA, transient ischemic attack.
*Adjusted for age, sex and ethnicity.
†Adjusted for age, natural log of the ratio of total cholesterol to high-density lipoprotein cholesterol, and diabetes for men and age, natural log of the ratio of total cholesterol to
high-density lipoprotein cholesterol, natural log of systolic blood pressure, diabetes, and smoking for women.
‡Adjusted for age, sex, ethnicity, diabetes mellitus, current smoking, history of heart failure, history of myocardial infarction, body mass index, systolic blood pressure, low-density
lipoprotein, estimated glomerular filtration rate, left ventricular mass index, left ventricular ejection fraction, and left ventricular diastolic function.
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increased risk, respectively) were somewhat attenuated but
remained significant. In the fully adjusted models that
included estimated glomerular filtration rate and LV structural
and functional parameters, the highest quartile of both BNP
and NT-proBNP remained predictive of HF hospitalization,
nonfatal MI, CV death, and MACE, whereas only the highest
quartile of NT-proBNP remained significantly associated with
CVA/TIA (Table 3).
Calibration metrics for risk models used in the receiver
operating characteristic curve analyses were as follows:
BNP alone, P=0.01; NT-proBNP alone, P=0.08; clinical risk
factors, P=0.007; clinical risk factors plus BNP, P=0.20;
clinical risk factors plus NT-proBNP, P=0.16. In receiver
operating characteristic curve analyses, NT-proBNP had a
stronger association with MACE than did BNP (Table 4). We
next evaluated and compared the marginal contribution of
adding BNP and NT-proBNP to a clinical risk factor model
that included age, natural log of the ratio of total
cholesterol to high-density lipoprotein cholesterol, and
diabetes for men and age, natural log of the ratio of total
cholesterol to high-density lipoprotein cholesterol, natural
log of systolic blood pressure, diabetes, and smoking for
women. The addition of BNP and the addition of NT-proBNP
to the clinical predictors improved the C statistic signifi-
cantly for the prediction of MACE, with a significantly higher
C statistic for the model including clinical risk factors and
NT-proBNP than the model including clinical risk factors and
BNP. Improvement in the category-free NRI for the predic-
tion of MACE was stronger for NT-proBNP (Table 5). For
NT-proBNP, the improvement in NRI was driven more by
downward risk classification of patients without MACE (35%)
than by upward risk classification of patients with MACE
(29%). As with the NRI, the IDI was higher with the addition
of NT-proBNP to the clinical model (0.16; 95% CI: 0.11 to
0.20) than with the addition of BNP (0.11; 95% CI: 0.07
to 0.14).
Discussion
We evaluated the association of BNP and NT-proBNP with
adverse CV events in a cohort of patients with stable CHD
and found that both BNP and NT-proBNP were associated
with adverse CV events, including HF hospitalizations, MI,
CVA/TIA, and CV deaths; however, NT-proBNP was superior
to BNP for reclassifying risk of MACE. Our study expands
the literature by performing a thorough head-to-head
comparison between BNP and NT-proBNP for the prediction
of adverse CV events over a long follow-up period in a
large, well-characterized, outpatient population with stable
CHD.
Although both BNP and NT-proBNP levels have been
found to be inversely associated with long-term survival in
patients with stable CHD,5,6,10,23 it has not been established
whether one outperforms the other for the prediction of
adverse CV events in stable CHD. Richards et al found that
BNP and NT-proBNP performed similarly in their ability to
predict HF and all-cause mortality in patients with stable
CHD (n=1049).9 This study, however, was limited to those 2
outcomes and to a 12-month follow-up period. In another
relevant study, Omland et al examined a population with
stable CHD and preserved systolic function enrolled in the
Prevention of Events With Angiotensin-Converting Enzyme
Inhibition (PEACE) trial (n=3761) and found that although
both BNP and NT-proBNP predicted HF events over a median
follow-up period of 4.8 years, NT-proBNP was also associ-
ated with greater risk of CV death and stroke.8 In this study,
neither marker appeared to significantly increase the risk of
MI. In our study, we noted an independent association
between both BNP and NT-proBNP and the combined
outcome of HF hospitalization, MI, CVA/TIA, or CV death.
Moreover both BNP and NT-proBNP were associated with
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Figure. Percentage of participants with cardiovascular out-
comes by quartiles of BNP and NT-proBNP. Bar graph illustrating
the percentage of participants in each quartile of BNP level (A)
and NT-proBNP level (B) with hospitalization for HF, nonfatal MI,
stroke or TIA, CV death, or any of these events. BNP indicates
brain-type natriuretic peptide; CV, cardiovascular; HF, heart
failure; MI, myocardial infarction; NT-proBNP, amino-terminal
fragment of the BNP prohormone; TIA, transient ischemic attack.
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the individual outcomes of HF, MI, and CV death. Although
neither BNP nor NT-proBNP was associated with CVA/TIA
when modeled as a continuous variable, the highest levels of
NT-proBNP were predictive of CVA/TIA independent of
clinical predictors and LV structure and function. The
differences between the results of our study and those
reported by Richards et al9 and Omland et al8 may be due
differences in the populations studied, in the follow-up
periods, in the covariates used, or in the assays used to
measure BNP and NT-proBNP levels.
In our receiver operating characteristic curve analyses,
the addition of both NT-proBNP and BNP to a clinical model
composed of risk factors for secondary events in the
Framingham study resulted in significant improvement of the
C statistic. For these models containing clinical risk factors
and BNP or NT-proBNP, there was no evidence of poor
model calibration (goodness of fit P>0.10).The significantly
improved C statistic likely reflects the known robustness of
natriuretic peptide levels for the prediction of MACE;
however, the addition of NT-proBNP resulted in a signifi-
cantly greater improvement in the C statistic than the
addition of BNP. Moreover, the results of the category-free
NRI and IDI analyses suggest that NT-proBNP may provide
greater incremental prognostic value than BNP when added
to clinical predictors for the prediction of adverse CV events.
Our findings expand on those of a previous study that
showed NT-proBNP provides incremental prognostic infor-
mation for the prediction of adverse CV events in lower risk
patients with CV risk factors.24 The magnitude of the NRI
achieved with the addition of NT-proBNP to traditional
clinical risk factors and echocardiographic predictors is
similar to that obtained with the addition of flow-mediated
dilation or coronary artery calcium scores to the Framing-
ham risk score.25,26
Table 3. Association of BNP and NT-proBNP With Cardiovascular Outcomes
BNP (Quartile IV vs I) NT-proBNP (Quartile IV vs I)
HR* (95% CI) P Value§ HR* (95% CI) P Value§
HF
Model 1* 14.79 (7.38 to 29.66) <0.001 26.83 (11.62 to 61.93) <0.001
Model 2† 15.21 (7.54 to 30.68) <0.001 25.69 (11.10 to 59.42) <0.001
Model 3‡ 6.33 (1.10 to 4.24) <0.001 9.82 (3.69 to 26.17) <0.001
Nonfatal MI
Model 1* 3.57 (2.02 to 6.31) <0.001 4.20 (2.02 to 6.31) <0.001
Model 2† 3.55 (1.98 to 6.38) <0.001 3.97 (2.17 to 7.26) <0.001
Model 3‡ 2.16 (1.10 to 4.24) 0.10 2.39 (1.15 to 4.96) 0.04
CVA/TIA
Model 1* 2.42 (1.20 to 4.90) 0.005 3.69 (1.71 to 7.96) <0.001
Model 2† 2.46 (1.19 to 5.10) 0.006 3.73 (1.67 to 8.31) <0.001
Model 3‡ 1.84 (0.77 to 4.39) 0.08 3.01 (1.12 to 8.08) 0.02
CV death
Model 1* 3.66 (2.10 to 6.40) <0.001 7.19 (3.71 to 13.90) <0.001
Model 2† 3.90 (2.19 to 6.93) <0.001 6.82 (3.51 to 13.23) <0.001
Model 3‡ 2.17 (1.10 to 4.28) 0.01 3.24 (1.50 to 6.99) 0.001
Any event
Model 1* 3.09 (2.31 to 4.14) <0.001 4.29 (3.18 to 5.79) <0.001
Model 2† 3.36 (2.49 to 4.53) <0.001 4.36 (3.21 to 5.93) <0.001
Model 3‡ 2.02 (1.41 to 2.87) <0.001 2.43 (1.66 to 2.56) <0.001
BNP indicates brain-type natriuretic peptide; CV, cardiovascular; CVA, cerebral vascular accident; HF, heart failure; HR, hazard ratio; MI, myocardial infarction; NT-proBNP, amino-terminal
fragment of the BNP prohormone; TIA, transient ischemic attack.
*Adjusted for age, sex and ethnicity.
†Adjusted for age, natural log of the ratio of total cholesterol to high-density lipoprotein cholesterol, and diabetes for men and age, natural log of the ratio of total cholesterol to high-
density lipoprotein cholesterol, natural log of systolic blood pressure, diabetes, and smoking for women.
‡Adjusted for age, sex, ethnicity, diabetes mellitus, current smoking, history of HF, history of MI, body mass index, systolic blood pressure, low-density lipoprotein, estimated glomerular
filtration rate, left ventricular mass index, left ventricular ejection fraction, and left ventricular diastolic function.
§P value is for trend across quartiles.
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Differences in half-life and clearance mechanisms
between the 2 biomarkers may explain why BNP and NT-
proBNP may not be equivalent markers of adverse CV
outcomes.27 Although both BNP and NT-proBNP levels are
thought to be inversely related to renal function, BNP is
further cleared by neutral endopeptidases and the natriuretic
peptide C receptor.28 However, several studies have also
shown that BNP and NT-proBNP levels are similarly affected
in patients with mild and moderate renal dysfunction.29,30 In
addition, the half-life of NT-proBNP is significantly longer
than that of BNP.27 These differences may contribute to the
higher circulating NT-proBNP levels observed in many
physiologic and pathologic states. Despite these differences,
we found that both BNP and NT-proBNP were similarly
associated with adverse CV outcomes after adjustment for
renal function.
Although both BNP and NT-proBNP show significant
biological variation, the intraindividual variability is greater
for BNP than NT-proBNP in stable outpatients with HF.31 This,
together with its longer in vivo half-life, may make NT-proBNP
a better reflector of longer term physiologic changes than
BNP. In addition, although NT-proBNP is very stable under
refrigerated storage, there are concerns that BNP may
degrade faster than NT-proBNP at room temperature as well
as in frozen samples.28,32 This potential difference in rates of
degradation may have influenced our findings because NT-
proBNP levels were measured in 2005 and BNP levels were
measured in 2013; however, we have previously established
the long-term stability of proteins in the frozen plasma
samples in the Heart and Soul Study. To test both the
reliability of our samples and the stability of frozen proteins,
we measured NT-proBNP levels (using the Roche Diagnostics
Elecsys proBNP assay) in frozen plasma samples in 2005
and in 2012 and found that, among 979 participants,
the correlation was 0.95 between the 2 NT-proBNP
measurements. We repeated a similar analysis with cystatin
C by measuring levels in 2006 and in 2010 and found that,
among 989 participants, the correlation was 0.96 between
the 2 cystatin C measurements. Moreover, the strong
correlation between NT-proBNP and BNP levels in the current
study, similar to or better than that reported in previous
studies in which the BNP and NT-proBNP levels were
measured at closer time points,8,9 argues against significant
degradation of BNP. Although there were significant differ-
ences in the analytic characteristics of the assays that we
used to measure BNP and NT-proBNP levels, this strong
correlation between BNP and NT-proBNP levels across a wide
range of values also argues against these real and potential
differences in analytic characteristics of the 2 assays fully
explaining the differences that we observed in the perfor-
mance of the 2 biomarkers as prognostic indicators.
Study Limitations
This study had several limitations. Because our study
population was composed predominately of older men in
an urban setting with stable CHD, these findings may not be
generalizable to other populations and disease states.
Table 4. Prediction of Adverse Cardiovascular Events
Assessed by Receiver Operating Characteristic Curve Analysis
Model C Statistic (95% CI) Comments
1. BNP alone 0.70 (0.66 to 0.74)
2. NT-proBNP
alone
0.74 (0.70 to 0.77) P<0.001 vs BNP alone
3. Clinical risk
factors*
0.63 (0.60 to 0.67)
4. Clinical risk
factors*+BNP
0.72 (0.69 to 0.76) P<0.001 vs clinical
risk factors
5. Clinical risk
factors*+
NT-proBNP
0.76 (0.73 to 0.79) P<0.001 vs clinical
risk factors
P<0.001 for model
4 vs 5
BNP indicates brain-type natriuretic peptide; CI, confidence interval; NT-proBNP, amino-
terminal fragment of the BNP prohormone.
*Clinical risk factor model includes age, natural log of the ratio of total cholesterol to
high-density lipoprotein cholesterol, and diabetes for men and age, natural log of the ratio
of total cholesterol to high-density lipoprotein cholesterol, natural log of systolic blood
pressure, diabetes, and smoking for women.
Table 5. Net Reclassification Improvement in Predicting Risk of Cardiovascular Events With the Addition of BNP or NT-proBNP to a
Clinical Risk Prediction Model*
Proportion of Patients
With Events Who Were
Reclassified (95% CI)
Proportion of Patients
Without Events Who Were
Reclassified (95% CI) Net Reclassification Improvement
+BNP 29% (22%, 38%) 27% (20%, 35%) 56% (45%, 70%)
+NT-proBNP 29% (21%, 39%) 35% (29%, 43%) 65% (52%, 80%)
BNP indicates brain-type natriuretic peptide; CI, confidence interval; NT-proBNP, amino-terminal fragment of the BNP prohormone.
*Clinical risk prediction model includes age, natural log of the ratio of total cholesterol to high-density lipoprotein cholesterol, and diabetes for men and age, natural log of the ratio of total
cholesterol to high-density lipoprotein cholesterol, natural log of systolic blood pressure, diabetes, and smoking for women.
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Moreover, HF events were defined as hospitalizations, and
patients presenting with signs and symptoms of HF in the
outpatient setting were not included. Some of the attenu-
ation of risk of adverse events associated with BNP and NT-
proBNP with adjustment for parameters of LV structure and
function could have resulted from the fact that 15% of the
participants could not be assigned unambiguously to an LV
diastolic function category and thus had a missing value for
this covariate. As discussed, differences in the in vitro
stability and biological variation of BNP and NT-proBNP, in
the analytic characteristics of the assays, and in the time
point of testing, along with 1 additional freeze–thaw cycle
for BNP, may also have played a role in producing the
differences in their predictive value. However, as discussed,
the long-term stability of proteins in the frozen blood
samples in the Heart and Soul Study and the strong
correlation between BNP and NT-proBNP across a range of
values make it unlikely that these factors fully explain the
findings observed in this study.
Conclusion
In patients with stable CHD, both BNP and NT-proBNP are
strong predictors of adverse CV events; however, when added
to clinical risk factors, NT-proBNP outperforms BNP in risk
classification for adverse CV events.
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